
DIRECTIONS

NATIONAL HEALTH SERVICE, ENGLAND

The General Medical Services Statement of Financial Entitlements (Amendment) Directions 2024

The Secretary of State gives the following Directions in exercise of the powers conferred by sections 87, 272(7) and (8) and 273(1) of the National Health Service Act 2006(a).

In accordance with section 87(4) of that Act, the Secretary of State has consulted with the body appearing to the Secretary of State to be representative of persons to whose remuneration these Directions relate.

Citation, commencement, extent, application and interpretation

1.—(1) These Directions may be cited as the General Medical Services Statement of Financial Entitlements (Amendment) Directions 2024.

(2) These Directions come into force on 1st September 2024 and except as otherwise provided for in paragraph (3), have effect from that day.

(3) Direction 2(2) and 2(3) have effect from 1st April 2024.

(4) These Directions are given to NHS England.

(5) These Directions extend to England and Wales and apply to England only.

(6) In these Directions, “the Principal Directions” means the General Medical Services Statement of Financial Entitlements Directions 2024(b).

Amendment of the Principal Directions—

2.—(1) The Principal Directions are amended as follows.

(2) In Part 1 (global sum)—

(a) In Section 3(4), for “£107.57” substitute “£112.50”; and

(b) In Section 3(9)(d), for “£107.57” substitute “£112.50”.

(3) In Part 4 (payments for specific purposes)—

(a) In Section 9(5)(a), for “£1,143.06” substitute “£1,211.64”,

(b) In Section 9(5)(b), for “£1751.52” substitute “£1,856.61”,

(c) In Section 10(5), for “£1,751.52” substitute “£1,856.61”,

(d) In Section 11(5), for “£1,131.74” substitute “£1,199.64”,

(e) In Section 12(3), for “£133.68” substitute “£141.70” and

(a) 2006 c. 41. Section 87 is amended by paragraph 1 (1) and (2) of Schedule 1 to the Health and Care Act 2022 (c. 31). By virtue of section 271(1) of the National Health Service Act 2006, the powers conferred by these sections are exercisable by the Secretary of State only in relation to England.

(b) The Directions were signed on 25th March 2024. Copies of the Directions are available at www.gov.uk/government/publications/nhs-primary-medical-services-directions-2013. Hard copies can be obtained from the Department of Health and Social Care, 4th Floor, 39 Victoria Street, London SW1H 0EU.

(f) In Section 12(7), for “£1,131.74” substitute “£1,199.64”.

(4) In Part 5 (vaccines and immunisations)—

(a) In Section 19 (general)—


(i) In Table 2 (adult routine immunisation schedule) at the end insert—

“Aged 75 years on or after 1 September 2024 and at least 75 years at the point of vaccination, remaining eligible until attaining age 80 years	Respiratory Syncytial Virus (RSV)	1 dose of RSV	Call/recall when become eligible. Opportunistic or if requested thereafter until aged 80 years
Aged 75-78 years on 31 August 2024 and at the point of vaccination, remaining eligible until attaining 80 years	Respiratory Syncytial Virus (RSV)	1 dose of RSV	Call/recall at the earliest opportunity and prior to 31 August 2025 Opportunistic or if requested thereafter until aged 80 years
Aged 79 years on 31 August 2024 and eligible until 31 August 2025	Respiratory Syncytial Virus (RSV)	1 dose of RSV	Call/recall at the earliest opportunity and prior to 31 August 2025
Individuals who are pregnant from 28 weeks	Respiratory Syncytial Virus (RSV)	1 dose of RSV	Opportunistic or if requested”

(ii) In Table 3 (selective immunisation schedule) for the final row substitute—

“Pregnant women from 16 weeks of pregnancy	Pertussis	ADACEL (Tdap) dTap/IPV(Boostrix - IPV or Repavax)(a)	Opportunistic or if requested”
--	-----------	--	--------------------------------

Signed by authority of the Secretary of State for Health and Social Care.



Mark Joannides

A member of the Senior Civil Service
Department for Health and Social Care

Address: 39 Victoria Street, London SW1H
0EH
28th August 2024

(a) Boostrix-IPV or REPEVAX should be given to pregnant women if they have a known severe latex allergy or where ADACEL is not available and to obtain it would result in a delay in vaccination.